Core Insights - Perimeter Medical Imaging AI, Inc. is participating in the "Take the Lead in Breast Cancer Care" summit, which gathers leading breast cancer physicians to discuss advancements in patient care [1][3] - The company's S-Series OCT technology, which received FDA clearance in 2021, allows surgeons to visualize margins during surgery, and an AI-assisted version is currently under FDA evaluation [2][4] Company Overview - Perimeter Medical Imaging AI is based in Toronto and Dallas, focusing on transforming cancer surgery with advanced imaging tools that provide real-time, ultra-high-resolution visualization of excised tissues at the cellular level [4] - The Perimeter S-Series OCT system is FDA-cleared and available across the U.S., while the investigational Perimeter B-Series OCT with ImgAssist AI is undergoing a pivotal clinical trial supported by a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas [4][5] Industry Context - The summit features multi-disciplinary discussions among surgeons, oncologists, pathologists, and genetic specialists, aimed at exploring innovative diagnostics and therapeutic discoveries to improve patient outcomes [3]

Core Insights - Perimeter Medical Imaging AI, Inc. is showcasing its S-Series OCT technology for real-time margin visualization during breast conserving surgery at the 2025 Annual Clinical Assembly [1][2][3] Company Overview - Perimeter Medical Imaging AI is a commercial-stage medical technology company based in Toronto and Dallas, focused on transforming cancer surgery with advanced imaging tools [4] - The S-Series OCT system has received FDA clearance in 2021 and provides real-time, cross-sectional visualization of excised tissues at the cellular level [4] - The investigational Perimeter B-Series OCT with ImgAssist AI is currently under evaluation in a pivotal clinical trial, supported by a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas [4] Technology and Application - Dr. Amelia Tower's presentation emphasizes the importance of advanced imaging technologies like the S-Series OCT in reducing re-excision rates and enhancing surgical precision [3][2] - The S-Series OCT allows surgeons to visualize disease at the cellular level in real-time, potentially reducing the stress and delays associated with re-excisions [3] Event Participation - The 2025 Annual Clinical Assembly, sponsored by the American College of Osteopathic Surgeons, gathers over 1,200 multi-disciplinary surgeons for networking and continuing medical education [3]

Core Insights - Nanox Imaging Ltd has announced a collaboration with Monarch Medical Management and Billing LLC to deploy advanced imaging solutions across various healthcare segments, including workers' compensation, nursing homes, and outpatient clinics [1][2][4] Group 1: Collaboration Details - The collaboration aims to establish a comprehensive imaging network by deploying Nanox's technology across Monarch's associated healthcare facilities, with over a dozen initial sites identified for a proof-of-concept phase [2] - Nanox's advanced imaging services will be accessible to patients in multiple care settings, including the Nanox.ARC system, AI-powered software for analyzing CT scans, and teleradiology services [3][4] Group 2: Strategic Goals - The collaboration addresses critical imaging access challenges by providing faster access to high-quality imaging services, which can accelerate accurate diagnosis and treatment decisions for patients [4] - Nanox's vision includes expanding its technology reach beyond hospital settings, aiming for a seamless end-to-end solution from scan to diagnosis, leveraging AI for improved efficiency in medical imaging [6] Group 3: Company Background - Nanox is focused on transitioning the world to preventive healthcare through affordable medical imaging technologies based on advanced AI and proprietary digital X-ray sources [5] - The Nanox ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all aimed at enhancing early detection and treatment to improve health outcomes globally [6]

Core Insights - Izotropic Corporation is initiating strategic awareness initiatives in anticipation of the commercialization of its IzoView Breast CT Imaging System, which aims to enhance breast cancer screening and diagnosis [1][2]. Group 1: Awareness Campaign - The awareness efforts will focus on educating global audiences about the transformative value of dedicated breast CT technology, highlighting IzoView's unique features and competitive advantages [2][5]. - The campaign will incorporate emerging trends in breast imaging, regulatory frameworks, and market growth forecasts to contextualize IzoView's potential [2]. Group 2: Communication Channels - Izotropic will launch a podcast series to discuss company news and milestones, providing timely commentary on corporate updates and relevant developments in the breast imaging sector [3]. - A dedicated online platform, breastct.com, will be introduced to feature articles about breast CT technology and the company's progress, evolving into a comprehensive educational resource over time [4]. Group 3: Strategic Alignment - The awareness strategy is developed in collaboration with Izotropic's capital markets and industry advisory team, focusing on aligning investor engagement and communications with long-term regulatory and commercialization objectives [5].